Category - Developments

Developments

ProMIS announces new AZ program

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Ab), are implicated in the...

July 14, 2016

Developments

Congress passes Comprehensive Addiction and Recovery Act

The United States Senate on Wednesday voted overwhelmingly to pass the Comprehensive Addiction and Recovery Act (CARA). The Senate vote follows a similar near-unanimous vote in the House of Representatives last week and...

July 14, 2016

Developments

Braeburn provides update on training sessions for Probuphine

Healthcare provider training and certification for Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant will take place on July 15-17 in Denver by Titan’s marketing partner, closely-held Braeburn Pharmaceuticals. The...

July 12, 2016

Developments

Buprenorphine patient limit raised to 275

The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine. The move was part of several announced by the...

July 7, 2016

Developments

FDA accepts Revive’s IND for Phase 2 bucillamine study

The FDA has accepted an IND from Revive Therapeutics (OTCQB:RVVTF; TSX-V:RVV) for a Phase 2 clinical study of bucillamine for the treatment of cystinuria. “This marks another significant milestone for Revive and...

July 6, 2016

Developments

Dipexium, Tandem Diabetes make Feltl Best Ideas list

Dipexium Pharmaceuticals (NASDAQ:DPRX) and Tandem Diabetes (NASDAQ:TNDM) have made Feltl & Co.’s Best Ideas list for the second half this year. Analyst Ben Haynor writes that top-line data for Dipexium’s two Phase 3...

July 5, 2016

Developments

Merck KGaA gets approval for Juniper’s OneCrinone in Japan

Merck KGaA of Germany (XETRA:MRK.DE) has received approval from the Japanese Ministry of Health, Labour and Welfare for Juniper Pharmaceuticals’ (NASDAQ:JNP) OneCrinone 90 mg (progesterone) for the indication of luteal...

July 5, 2016

Developments

Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma. No statistically significant differences...

July 5, 2016

Developments

Titan Pharma added to Russell 3000 index

Titan Pharmaceuticals (NASDAQ:TTNP) has been added to the broad U.S. market Russell 3000 index and the small-cap Russell 2000 index as part of Russell Investments’ annual reconstitution of its stock indexes, effective...

June 27, 2016

Developments

Cellectar shows potential against triple negative breast cancer

Cellectar Biosciences (NASDAQ:CLRB) has announced the results of the first phase of a NCI-funded Small Business Innovation Research (SBIR) Phase 1 contract for a study of CLR 125, a radiotherapeutic isotope, which may...

June 23, 2016

Category - Developments

ProMIS announces new AZ program

Congress passes Comprehensive Addiction and Recovery Act

Braeburn provides update on training sessions for Probuphine

Buprenorphine patient limit raised to 275

FDA accepts Revive’s IND for Phase 2 bucillamine study

Dipexium, Tandem Diabetes make Feltl Best Ideas list

Merck KGaA gets approval for Juniper’s OneCrinone in Japan

Can-Fite unit fails Phase 2 glaucoma trial

Titan Pharma added to Russell 3000 index

Cellectar shows potential against triple negative breast cancer

General

More